Cargando…
Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol
BACKGROUND: Respiratory syncytial virus (RSV) infection is an important cause of hospitalization and death in young children. The majority of deaths (99%) occur in low- and lower-middle-income countries (LMICs). Vaccines against RSV infection are underway. To obtain access to RSV interventions, LMIC...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380869/ https://www.ncbi.nlm.nih.gov/pubmed/34425773 http://dx.doi.org/10.1186/s12879-021-06544-3 |
_version_ | 1783741259030986752 |
---|---|
author | Löwensteyn, Yvette N. Mazur, Natalie I. Nair, Harish Willemsen, Joukje E. van Thiel, Ghislaine Bont, Louis |
author_facet | Löwensteyn, Yvette N. Mazur, Natalie I. Nair, Harish Willemsen, Joukje E. van Thiel, Ghislaine Bont, Louis |
author_sort | Löwensteyn, Yvette N. |
collection | PubMed |
description | BACKGROUND: Respiratory syncytial virus (RSV) infection is an important cause of hospitalization and death in young children. The majority of deaths (99%) occur in low- and lower-middle-income countries (LMICs). Vaccines against RSV infection are underway. To obtain access to RSV interventions, LMICs depend on support from Gavi, the Vaccine Alliance. To identify future vaccine target populations, information on children with severe RSV infection is required. However, there is a lack of individual patient-level clinical data on instances of life-threatening RSV infection in LMICs. The RSV GOLD III—ICU Network study aims to describe clinical, demographic and socioeconomic characteristics of children with life-threatening RSV infection in Gavi-eligible countries. METHODS: The RSV GOLD-III—ICU Network study is an international, prospective, observational multicenter study and will be conducted in 10 Gavi-eligible countries at pediatric intensive care units and high-dependency units (PICUs/HDUs) during local viral respiratory seasons for 2 years. Children younger than 2 years of age with respiratory symptoms fulfilling the World Health Organization (WHO) “extended severe acute respiratory infection (SARI)” case definition will be tested for RSV using a molecular point-of-care (POC) diagnostic device. Patient characteristics will be collected through a questionnaire. Mortality rates of children admitted to the PICU and/or HDU will be calculated. DISCUSSION: This multicenter descriptive study will provide a better understanding of the characteristics and mortality rates of children younger than 2 years with RSV infection admitted to the PICU/HDU in LMICs. These results will contribute to knowledge on global disease burden and awareness of RSV and will directly guide decision makers in their efforts to implement future RSV prevention strategies. Trial registration number: NL9519, May 27, 2021 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06544-3. |
format | Online Article Text |
id | pubmed-8380869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83808692021-08-23 Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol Löwensteyn, Yvette N. Mazur, Natalie I. Nair, Harish Willemsen, Joukje E. van Thiel, Ghislaine Bont, Louis BMC Infect Dis Study Protocol BACKGROUND: Respiratory syncytial virus (RSV) infection is an important cause of hospitalization and death in young children. The majority of deaths (99%) occur in low- and lower-middle-income countries (LMICs). Vaccines against RSV infection are underway. To obtain access to RSV interventions, LMICs depend on support from Gavi, the Vaccine Alliance. To identify future vaccine target populations, information on children with severe RSV infection is required. However, there is a lack of individual patient-level clinical data on instances of life-threatening RSV infection in LMICs. The RSV GOLD III—ICU Network study aims to describe clinical, demographic and socioeconomic characteristics of children with life-threatening RSV infection in Gavi-eligible countries. METHODS: The RSV GOLD-III—ICU Network study is an international, prospective, observational multicenter study and will be conducted in 10 Gavi-eligible countries at pediatric intensive care units and high-dependency units (PICUs/HDUs) during local viral respiratory seasons for 2 years. Children younger than 2 years of age with respiratory symptoms fulfilling the World Health Organization (WHO) “extended severe acute respiratory infection (SARI)” case definition will be tested for RSV using a molecular point-of-care (POC) diagnostic device. Patient characteristics will be collected through a questionnaire. Mortality rates of children admitted to the PICU and/or HDU will be calculated. DISCUSSION: This multicenter descriptive study will provide a better understanding of the characteristics and mortality rates of children younger than 2 years with RSV infection admitted to the PICU/HDU in LMICs. These results will contribute to knowledge on global disease burden and awareness of RSV and will directly guide decision makers in their efforts to implement future RSV prevention strategies. Trial registration number: NL9519, May 27, 2021 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06544-3. BioMed Central 2021-08-23 /pmc/articles/PMC8380869/ /pubmed/34425773 http://dx.doi.org/10.1186/s12879-021-06544-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Löwensteyn, Yvette N. Mazur, Natalie I. Nair, Harish Willemsen, Joukje E. van Thiel, Ghislaine Bont, Louis Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol |
title | Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol |
title_full | Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol |
title_fullStr | Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol |
title_full_unstemmed | Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol |
title_short | Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol |
title_sort | describing global pediatric rsv disease at intensive care units in gavi-eligible countries using molecular point-of-care diagnostics: the rsv gold-iii study protocol |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380869/ https://www.ncbi.nlm.nih.gov/pubmed/34425773 http://dx.doi.org/10.1186/s12879-021-06544-3 |
work_keys_str_mv | AT lowensteynyvetten describingglobalpediatricrsvdiseaseatintensivecareunitsingavieligiblecountriesusingmolecularpointofcarediagnosticsthersvgoldiiistudyprotocol AT mazurnataliei describingglobalpediatricrsvdiseaseatintensivecareunitsingavieligiblecountriesusingmolecularpointofcarediagnosticsthersvgoldiiistudyprotocol AT nairharish describingglobalpediatricrsvdiseaseatintensivecareunitsingavieligiblecountriesusingmolecularpointofcarediagnosticsthersvgoldiiistudyprotocol AT willemsenjoukjee describingglobalpediatricrsvdiseaseatintensivecareunitsingavieligiblecountriesusingmolecularpointofcarediagnosticsthersvgoldiiistudyprotocol AT vanthielghislaine describingglobalpediatricrsvdiseaseatintensivecareunitsingavieligiblecountriesusingmolecularpointofcarediagnosticsthersvgoldiiistudyprotocol AT bontlouis describingglobalpediatricrsvdiseaseatintensivecareunitsingavieligiblecountriesusingmolecularpointofcarediagnosticsthersvgoldiiistudyprotocol AT describingglobalpediatricrsvdiseaseatintensivecareunitsingavieligiblecountriesusingmolecularpointofcarediagnosticsthersvgoldiiistudyprotocol |